EFFICACY OF IMMUNOMODULATORS AND ANTIOXIDANTS IN THE CORRECTION OF IMPAIRED IMMUNE STATUS PARAMETERS IN PATIENTS WITH ADENOMYOSIS

O.Yu. Ivanova; Olga V. Telegina; A. A. Konoplya

doi:10.15789/1563-0625-eoi-2045

EFFICACY OF IMMUNOMODULATORS AND ANTIOXIDANTS IN THE CORRECTION OF IMPAIRED IMMUNE STATUS PARAMETERS IN PATIENTS WITH ADENOMYOSIS

O.Yu. Ivanova, Olga V. Telegina, A. A. Konoplya

In: Medical Immunology (Russia) · 2021 · vol. 23(4) , pp. 941–948 · doi:10.15789/1563-0625-eoi-2045 · W3205632531

article OA: diamond CC0 ⤵ 1 in-corpus citation

🔓 Open OA copy View on OpenAlex View at publisher

⚙ AI-generated summary by claude@2026-06, 2026-06-10 ⓘ

This study investigated the efficacy of immunomodulators and antioxidants in correcting immune status parameters in adenomyosis patients, revealing optimal combinations that improve upon standard treatment alone.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 ⓘ

The study evaluated 70 women with adenomyosis (57 in the main cohort) and compared them with 23 gynecologically healthy controls, using clinical, ultrasound, and hysteroscopic confirmation of diagnosis, and measuring cytokine profiles and complement system activation at baseline and by day 15. All adenomyosis patients in the main cohort received standard treatment; within the cohort, subgroups additionally received different combinations of antioxidants and immunomodulators/membrane protectors, including sodium ribonucleate plus Hypoxen and phospholipids, or Inosine plus nicotinamide, riboflavin, succinic acid, meglumine acridoneacetate, and glycyrrhizic acid plus phospholipids. The authors report that adenomyosis was associated with increased systemic chemokines and pro-inflammatory cytokines (TNFα, IL-8, IL-1β, IL-6, IL-18) with decreased anti-inflammatory cytokines (IL-1ra, IL-4), along with complement activation and increased neutrophil oxygen-dependent activity, and that standard care alone showed insufficient laboratory-clinical effectiveness for correcting these immune changes. This paper is centrally about adenomyosis — it tests whether adding immunomodulators/antioxidants to standard treatment improves impaired systemic immune status parameters in adenomyosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

The aim of the study was to study the effectiveness of the use of immunomodulators and antioxidants in the correction of immune status parameters in patients with adenomyosis. 70 patients were examined, including 57 women (the main group), who were diagnosed with adenomyosis according to the results of a comprehensive clinical, ultrasound and hysteroscopic examination. The control group consisted of 23 gynecologically healthy women. After verification of the diagnosis, all patients with hypertension received standard treatment (SL) (clinical recommendations of the Ministry of Health of the Russian Federation from 2016). Among the female patients, 19 women received only SL (1 st subgroup). 38 exhaust gases examined, in addition to SL, received various combinations of antioxidant, immunomodulator, and membrane protector and were divided into two subgroups. The second subgroup included 20 patients in addition to the SL receiving sodium ribonucleate; Hypoxene and phospholipids. The third subgroup included 18 patients who additionally received Inosine + Nicotinamide + Riboflavin + Succinic acid; Meglumine acridone acetate, and glycyrrhizic acid + phospholipids. The analysis of the cytokine status and the compliment system was performed at the time of admission and by the 15 th day of observation. Detected changes of the cytokine status, complement system activation, increased oxygen-dependent activity of neutrophils in the peripheral blood (increased production of active oxygen forms as a result of respiratory burst) confirm the presence of immune inflammation on the systemic level. Insufficient clinical-laboratory efficacy of ST in the correction of immune changes has justified the use of drugs with immunomodulating, antioxidant, and membrane protective properties in the pharmacological therapy of adenomyosis, which have been successfully used in the treatment of other diseases with similar disorders.Optimal combinations of immunomodulators and antioxidants in the correction of the immune status of patients with adenomyosis were revealed. The study performed demonstrates the efficacy of correcting immune status parameters in patients with adenomyosis when the standard treatment is combined with antioxidant and immunomodulating agents.